Patents by Inventor Nicholas Charles Ray
Nicholas Charles Ray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9029373Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: August 5, 2014Date of Patent: May 12, 2015Assignee: Chiesi Farmaceutici S.p.A.Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
-
Publication number: 20150080375Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: ApplicationFiled: October 14, 2014Publication date: March 19, 2015Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
-
Patent number: 8957082Abstract: The subject invention provides compounds of formula (I): Including monomers and multimers thereof that are inhibitors of human neutrophil elastase (HNE) activity and are useful in the treatment of diseases or conditions in which HNE plays a part.Type: GrantFiled: April 17, 2012Date of Patent: February 17, 2015Assignee: Chiesi Farmaceutici S.p.AInventors: Nicholas Charles Ray, Harry Finch, Christine Edwards, Elizabeth O'Connor
-
Patent number: 8907094Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: December 7, 2012Date of Patent: December 9, 2014Assignee: Chiesi Farmaceutici S.p.A.Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
-
Publication number: 20140343055Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Applicant: Chiesi Farmaceutici S.p.AInventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
-
Publication number: 20140323470Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: ApplicationFiled: July 14, 2014Publication date: October 30, 2014Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Monique Bodil VAN NIEL, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
-
Patent number: 8835431Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.Type: GrantFiled: December 7, 2012Date of Patent: September 16, 2014Assignee: Chiesi Farmaceutici S.p.A.Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
-
Publication number: 20140018345Abstract: Compounds of formula (I): wherein R1, R2, R3, R5, R6, A1, A2, A3, A4 assume meanings as defined in formula (I) are inhibitors of neutrophil elastase.Type: ApplicationFiled: July 12, 2013Publication date: January 16, 2014Applicant: CHIESI FARMACEUTICI S.p.AInventors: Carmelida Capaldi, Robert Andrew Heald, Nicholas Charles Ray, Jonathan Mark Sutton
-
Publication number: 20120277275Abstract: Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases:Type: ApplicationFiled: April 24, 2012Publication date: November 1, 2012Applicant: PULMAGEN THERAPEUTICS (SYNERGY) LIMITEDInventors: Nicholas Charles Ray, Richard James Bull, Harry Finch, Marco van den Heuvel, Jose Antonio Bravo
-
Publication number: 20120202826Abstract: The subject invention provides compounds of formula (I): Including monomers and multimers thereof that are inhibitors of human neutrophil elastase (HNE) activity and are useful in the treatment of diseases or conditions in which HNE plays a part.Type: ApplicationFiled: April 17, 2012Publication date: August 9, 2012Inventors: Nicholas Charles RAY, Harry Finch, Christine Edwards, Elizabeth O'Connor
-
Patent number: 8198288Abstract: The subject invention provides compounds of formula (1): including monomers and multimers thereof that are inhibitors of human neutrophil elastase (HNE) activity and are useful in the treatment of diseases or conditions in which HNE plays a part.Type: GrantFiled: November 4, 2008Date of Patent: June 12, 2012Assignee: Pulmagen Therapeutics (Inflammation) LimitedInventors: Nicholas Charles Ray, Harry Finch, Christine Edwards, Elizabeth O'Connor
-
Publication number: 20110319446Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to whiType: ApplicationFiled: June 20, 2011Publication date: December 29, 2011Applicant: Argenta Discovery Ltd.Inventors: Harry Finch, Nicholas Charles Ray, Richard James Bull, Monique Bodil van Niel, Andrew Stephen Robert Jennings
-
PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST
Publication number: 20110245293Abstract: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a ?2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: August 11, 2009Publication date: October 6, 2011Applicant: AstraZeneca ABInventors: Barbara G. Avitabile, Nicholas Charles Ray, Alan John Nadin -
Publication number: 20110207770Abstract: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: August 11, 2009Publication date: August 25, 2011Applicants: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNERGY) LIMITEDInventors: Barbara G. Avitabile, Alan John Nadin, Nicholas Charles Ray
-
Patent number: 7994211Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5—Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom toType: GrantFiled: August 8, 2006Date of Patent: August 9, 2011Assignee: Argenta Discovery LimitedInventors: Nicholas Charles Ray, Andrew Stephen Robert Jennings
-
Patent number: 7858640Abstract: Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory components; in which: R1-R9 are various substituents; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10— wherein n is an integer from 0-1 and R10 is selected from various substituents; B is a direct bond or a divalent radical; R11 and R12 are selected from cvarious substituents; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid group, or a group of formula C?(O)NHSO2R6 or SO2NHC(?O)R6; and Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.Type: GrantFiled: September 29, 2006Date of Patent: December 28, 2010Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: Michael Colin Cramp, Rosa Arienzo, George Hynd, Peter Crackett, Yann Griffon, Trevor Keith Harrison, Nicholas Charles Ray, Harry Finch, John Gary Montana
-
Publication number: 20100144786Abstract: Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component.Type: ApplicationFiled: March 29, 2007Publication date: June 10, 2010Inventors: Michael Colin Cramp, Rosa Arienzo, George Hynd, Peter Crackett, Yann Griffon, Trevor Keith Harrison, Nicholas Charles Ray, Harry Finch, John Gary Montana
-
Publication number: 20100144852Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5—Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom toType: ApplicationFiled: August 8, 2006Publication date: June 10, 2010Applicant: ARGENTA DISCOVERY LIMITEDInventors: Harry Finch, Nicholas Charles Ray, Richard James Bull, Monique Bodil van Niel, Andrew Stephen Robert Jennings
-
Publication number: 20100137300Abstract: The specific compounds of this list: {7-cyano-2-methyl-1-[4-(morpholine-4-sutfonyl)benzyl]indolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro-4-(morpholine-4-sutfonyl)phenylsutfanyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl}acetic acid are ligands of the CRTH2 receptor and are useful in the treatment of respiratory diseases.Type: ApplicationFiled: March 21, 2007Publication date: June 3, 2010Inventors: George Hynd, Nicholas Charles Ray, Harry Finch, John Gary Montana, Michael Colin Cramp, Trevor Keith Harrison, Rosa Arienzo, Paul Blaney, Yann Griffon, David Middlemiss
-
Publication number: 20100113540Abstract: Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R1 is C1-C6-alkyl or hydrogen; and R2 is hydrogen or a group —R7, —Z—Y—R7, —Z—NR9R10; —Z—CO—NR9R10, —Z—NR9—[AE11]C(O)O—R7, or —Z—C(O)—R7; and R3 is a lone pair, or C1C6-alkyl; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring and R2 is a lone pair or a group —R7, —Z—Y—R7, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—[AE12]C(O)O—R7; or; —Z—C(O)—R7; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R7, —Z—Y—R7, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—[AE13]C(O)O—R7; or; —Z—C(O)—R7; and R3 is a lone pair, or C1-C6-alkyl; R4 and R5 are independently selected from the group consisting of aryl, ary-tfused-heterocycloalkyl, heteroaryl, C1-C6-alkyl, cycloalkyl; R6 is —OH, C1-C6-alkyl, C1-C6-alkoxy, hydroxy-C1-C6-alkyl, nitrile, a gType: ApplicationFiled: August 8, 2006Publication date: May 6, 2010Applicant: ARGENTA DISCOVERY LIMITEDInventors: Nicholas Charles Ray, Richard James Bull, Harry Finch, Marco van den Heuvel, Jose Antonio Bravo